Celldex will stop development of barzolvolimab in eosinophilic esophagitis, but it will continue progressing the drug in ...

The FDA has announced it will no longer accept clinical trials that involve sending US patients cells from US to China for ...

MTPA's oral therapy Radicava (edaravone) has shown decreased functional decline and improved survival in long-term ALS trials ...

UK-based Monument Therapeutics has joined forces with the Foundation for the National Institutes of Health (FNIH), US, to ...

A recently published study provides an incentive to explore what specific aspects of vegetarianism are protective.

Biodexa has enrolled the initial two subjects in the Phase III Serenta study of eRapa, involving individuals with FAP.

BioAge Labs has dosed the first subject in the Phase I study of BGE-102, under development initially for treating obesity.

Anocca has secured approximately Skr440m (around $46m) to primarily support the early-stage clinical trials of VIDAR-1.

This is the latest hit for Pfizer’s sickle cell disease portfolio after pulling Oxbryta from the market in 2024.

MASLD is among the most common types of chronic liver disease and is estimated to affect 30% of the global population.

THL Partners has announced its agreement to purchase Headlands Research, a clinical trial sites network, from KKR-managed ...

As antimicrobial resistance (AMR) escalates and chronic viral infections like human immunodeficiency virus (HIV) and herpes ...